
Vistim Labs enables clinicians to monitor dementia progression and treatment response using a single, noninvasive EEG. Their SaaS neurodiagnostic platform, CASBA ATN+, uses AI, machine learning, and advanced signal processing to convert EEGs into quantitative estimates of amyloid, tau, cognitive decline, and neurodegeneration, functionally mirroring PET and MRI biomarkers. The product is positioned as a clinical and research tool for routine therapy monitoring and precision neurology. Vistim Labs integrates into clinical workflows and is aimed at clinics and researchers treating neurodegenerative disease. The company targets scaling adoption in healthcare settings where repeatable, low-cost biomarker monitoring is needed.

Vistim Labs enables clinicians to monitor dementia progression and treatment response using a single, noninvasive EEG. Their SaaS neurodiagnostic platform, CASBA ATN+, uses AI, machine learning, and advanced signal processing to convert EEGs into quantitative estimates of amyloid, tau, cognitive decline, and neurodegeneration, functionally mirroring PET and MRI biomarkers. The product is positioned as a clinical and research tool for routine therapy monitoring and precision neurology. Vistim Labs integrates into clinical workflows and is aimed at clinics and researchers treating neurodegenerative disease. The company targets scaling adoption in healthcare settings where repeatable, low-cost biomarker monitoring is needed.
What: In-clinic brain imaging (Ceregram) that converts a single EEG into PET-relevant biomarker estimates (amyloid, tau, neurodegeneration).
Founded: 2021 (Sep 1, 2021)
Headquarters: Salt Lake City, Utah, United States
Lead founder / CEO: James Hamet
Funding: 3 disclosed rounds; latest: Grant (Jun 8, 2023); total funding reported: 817000 (USD)
Neurology / neurodegenerative disease monitoring and dementia care; point-of-care biomarker tracking.
2021
Medtech / Diagnostics (Biotechnology positioning noted)
“Alberta Innovates; GoAhead Ventures; PharmStars; Beresford Ventures; RK Hart Capital”